Baudax Bio Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
BXRX Nasdaq 8731 https://www.baudaxbio.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Baudax Bio Inc

Baudax Bio Announces Positive Results from 2nd Interim Analysis of Phase 2 Randomized Trial for BX1000 - Mar 27th, 2023 12:00 pm
Baudax Bio Reports 2022 Fourth Quarter and Annual Financial Results and Provides Business Update - Feb 23rd, 2023 1:00 pm
Baudax Bio Announces Positive Outcome of Interim Analysis of Phase II Randomized Trial for BX1000 - Jan 24th, 2023 1:00 pm
Baudax Bio Initiates Phase II Clinical Trial Evaluating BX1000 in Patients Undergoing Surgery - Dec 8th, 2022 1:00 pm
Baudax Bio Announces Closing of $5 Million Public Offering - Dec 6th, 2022 9:11 pm
Baudax Bio Announces Pricing of $5 Million Public Offering - Dec 2nd, 2022 7:46 pm
Baudax Bio Announces 1-for-40 Reverse Stock Split - Nov 30th, 2022 9:50 pm
Baudax Bio Reports Third Quarter 2022 Financial Results and Business Highlights - Nov 8th, 2022 9:09 pm
Baudax Bio Announces Distribution of Series B Preferred Stock to Holders of its Common Stock - Sep 19th, 2022 8:05 pm
Baudax Bio to Present at the 24th Annual H.C. Wainwright Healthcare Conference - Sep 8th, 2022 8:05 pm
Baudax Bio Announces Closing of $6.2 Million Public Offering - Sep 1st, 2022 6:56 pm
Baudax Bio Announces Pricing of $6.2 Million Public Offering - Aug 30th, 2022 2:04 am
Baudax Bio receives notice of allowance for U.S. Patent Application covering use of ANJESO® for the treatment of moderate to severe pain - Aug 22nd, 2022 12:00 pm
Baudax Bio Reports Second Quarter 2022 Financial Results and Business Highlights - Aug 11th, 2022 11:00 am
Baudax Bio Announces Dosing of First Cohort in First-in-Man, Phase I Clinical Study Evaluating BX2000 - Jun 1st, 2022 12:00 pm
Baudax Bio to Present at the H.C. Wainwright Annual Global Life Sciences Conference - May 18th, 2022 12:00 pm
Baudax Bio Announces $2.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - May 17th, 2022 11:00 pm
Baudax Bio Announces Date of Reconvened Annual Meeting of Shareholders - May 5th, 2022 9:00 pm
Baudax Bio Reports First Quarter 2022 Financial Results and Business Highlights - May 4th, 2022 9:00 pm
Baudax Bio to Report First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 5, 2022 - May 2nd, 2022 8:05 pm